Cubist Pharmaceuticals (FRA:CU6) Interest Expense : €-42.9 Mil (TTM As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Cubist Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cubist Pharmaceuticals's interest expense for the three months ended in Sep. 2014 was € -11.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2014 was €-42.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cubist Pharmaceuticals's Operating Income for the three months ended in Sep. 2014 was € 52.6 Mil. Cubist Pharmaceuticals's Interest Expense for the three months ended in Sep. 2014 was € -11.4 Mil. Cubist Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2014 was 4.62. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cubist Pharmaceuticals Interest Expense Historical Data

The historical data trend for Cubist Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cubist Pharmaceuticals Interest Expense Chart

Cubist Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Interest Expense

Get a 7-Day Free Trial

-14.33

-19.34

-23.88

-25.14

-27.45

Cubist Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Interest Expense	Get a 7-Day Free Trial															-6.68	-10.40	-10.41	-10.68	-11.38

Cubist Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-42.9 Mil.

Cubist Pharmaceuticals (FRA:CU6) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cubist Pharmaceuticals's Interest Expense for the three months ended in Sep. 2014 was €-11.4 Mil. Its Operating Income for the three months ended in Sep. 2014 was €52.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2014 was €654.6 Mil.

Cubist Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2014 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2014 )	/	Interest Expense (Q: Sep. 2014 )
	=	-1	*	52.62	/	-11.379
	=	4.62

The higher the ratio, the stronger the company's financial strength is.

Cubist Pharmaceuticals (FRA:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cubist Pharmaceuticals Inc (FRA:CU6) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cubist.com

Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.

Cubist Pharmaceuticals (FRA:CU6) Headlines

No Headlines